A CRO look­ing to build its man­u­fac­tur­ing side busi­ness has a new par­ent af­ter Keen­sight snaps up ma­jor­i­ty stake

Dutch CRO Symeres has looked to grow its man­u­fac­tur­ing side busi­ness, rec­og­niz­ing the ben­e­fit of syn­er­gy in con­tract re­search and pro­duc­tion. That dual mis­sion caught the eye of Keen­sight Cap­i­tal, a French in­vest­ment firm who has de­cid­ed to go all in and steer the ship.

Keen­sight on Tues­day said it would pick up a ma­jor­i­ty stake in Symeres from Gilde Health­care. Symeres spe­cial­izes in small mol­e­cules and pro­vides R&D ser­vices from pre­clin­i­cal dis­cov­ery to Phase I/II clin­i­cal stages of drug de­vel­op­ment along­side its man­u­fac­tur­ing of­fer­ings. The com­pa­ny is grow­ing, and Keen­sight will help the com­pa­ny grow its op­er­a­tion over the next few years, Keen­sight part­ner Amit Kar­na said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER